Integration Free IPS Cells-Derived Progenitors for Cardiac Regeneration
Integration Free IPS Cells-Derived Progenitors for Cardiac Regeneration
批准号:
8839043
负责人:
Muhammad Ashraf
金额:
$73.37万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2019-02-28
关键词:
AnimalsApoptosisAutologousBehaviorBiologyBlood VesselsCardiacCardiac MyocytesCardiovascular systemCell LineCell LineageCell TherapyCell surfaceCellsCharacteristicsChromatinCicatrixDNADataDevelopmentEngraftmentEnzymesEpigenetic ProcessExperimental Animal ModelFamily suidaeFibroblastsFibrosisGenerationsGeneticGenomeGoalsHealthHearing problemHeartHeart DiseasesHumanHypoxiaInfarctionIschemic PreconditioningMethodsModelingMolecular BiologyMusMuscle CellsMyoblastsMyocardialMyocardial InfarctionMyocardiumNatural regenerationNaturePatientsPhysiologyPluripotent Stem CellsPopulationProcessProteinsRecombinantsResearchRiskSignal TransductionSkeletal MuscleSkeletal MyoblastsSourceStagingStem cellsTechniquesTestingTherapeuticTissuesTransferaseTransplantationUltrasonographyUp-RegulationVascular Endothelial Growth FactorsViralViral Vectorattenuationbasecardiac regenerationdesignexperiencefunctional outcomesheart functionimprovedin vivoinduced pluripotent stem cellinhibitor/antagonistinnovationinterdisciplinary approachpluripotencypre-clinicalpreconditioningprogenitorpublic health relevanceregenerative therapyrepairedsmall moleculestemstem cell therapytranscription factortumorvector-induced
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The generation of induced pluripotent stem (iPS) cells is an innovative approach for generating autologous pluripotent stem cell lines for individualized cell therapy. Our research will use human skeletal muscle derived myoblasts rather than terminally differentiated fibroblasts for non-viral generation of iPS and their differentiation int cardiac progenitor cells. The hypothesis is that skeletal myoblasts (SMs) are superior candidates for induction to pluripotent state with fewer factors either alone or in combination with treatment with small molecules. Thus iPS derived cardiac progenitors may be readily generated with the use of cardiogenic small molecules, purified to generate off shelf universal cardiac cells. The direct generation of progenitors from iPS cells with specific small molecule may be a major current paradigm shift in stem cell therapy. We further propose that use of iPS derived cardiovascular progenitors will allow successful regeneration of infarcted myocardium without the risk of tumorgenecity. The hypotheses will be tested in the following specific Aims. Specific Aim-1will generate iPS cells from human SMs using small molecules; Specific Aim-2 will focus on developing strategies to direct iPS cells to cardiac and vascular progenitors; Specific Aim-3 will exploit the power of Ischemic preconditioning signaling in regulating survival and engraftment of iPS -progenitors in the ischemic tissue for effective regeneration; Specific Aim 4 will test that transplantation of iPS - progenitors and preconditioned progenitors effectivel regenerates infarcted myocardium and reverses fibrosis in murine and pre-clinical porcine heart models. The end points of the in vivo studies will be reversal of fibrosis through myoangiogenic differentiation of the engrafted progenitor cells, functional integration of developing cardiac myocytes into the host heart, attenuation of infarct size and the functional benefits in terms of improved global heart function. These studies will involve multidisciplinary approach which will employ state of the art molecular biology, histochemical and immunohistochemical techniques and well integrative physiology involving well established experimental animal model, and transthoracic ultrasonography for animal heart function. These studies are expected to facilitate robust cardiac differentiation and cardiomyocyte purification resulting in generation of unlimited number of cardiac progenitor cells from SM-iPS for restoring damaged myocardium without the risk of tumor formation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors
-
批准号:9687673
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2016
-
负责人:Muhammad Ashraf
-
依托单位:
Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors
-
批准号:9232058
-
项目类别:
-
资助金额:$54.18万
-
财政年份:2016
-
负责人:Muhammad Ashraf
-
依托单位:
Notch1/miR-322 Axis in Stem Cell Mediated Vascular Repair
-
批准号:9332457
-
项目类别:
-
资助金额:$62.14万
-
财政年份:2016
-
负责人:Muhammad Ashraf
-
依托单位:
Notch1/miR-322 Axis in Stem Cell Mediated Vascular Repair
-
批准号:9478676
-
项目类别:
-
资助金额:$62.14万
-
财政年份:2016
-
负责人:Muhammad Ashraf
-
依托单位:
Notch1/miR-322 Axis in Stem Cell Mediated Vascular Repair
-
批准号:9923003
-
项目类别:
-
资助金额:$62.14万
-
财政年份:2016
-
负责人:Muhammad Ashraf
-
依托单位:
Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors
-
批准号:10162502
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2016
-
负责人:Muhammad Ashraf
-
依托单位:
MicroRNA as mediators of angiogenesis & ischemic myocardial repair
-
批准号:8333130
-
项目类别:
-
资助金额:$54.28万
-
财政年份:2012
-
负责人:Muhammad Ashraf
-
依托单位:
MicroRNA as mediators of angiogenesis & ischemic myocardial repair
-
批准号:8837681
-
项目类别:
-
资助金额:$49.14万
-
财政年份:2012
-
负责人:Muhammad Ashraf
-
依托单位:
MicroRNA as mediators of angiogenesis & ischemic myocardial repair
-
批准号:9059179
-
项目类别:
-
资助金额:$49.88万
-
财政年份:2012
-
负责人:Muhammad Ashraf
-
依托单位:
MicroRNA as mediators of angiogenesis & ischemic myocardial repair
-
批准号:8657107
-
项目类别:
-
资助金额:$48.89万
-
财政年份:2012
-
负责人:Muhammad Ashraf
-
依托单位:
MicroRNA as mediators of angiogenesis & ischemic myocardial repair
-
批准号:8509782
-
项目类别:
-
资助金额:$47.49万
-
财政年份:2012
-
负责人:Muhammad Ashraf
-
依托单位:
iPS cells-derived progenitor cells for angiomyogenesis
-
批准号:8852679
-
项目类别:
-
资助金额:$71.5万
-
财政年份:2011
-
负责人:Muhammad Ashraf
-
依托单位:
iPS cells-derived progenitor cells for angiomyogenesis
-
批准号:8325050
-
项目类别:
-
资助金额:$28.61万
-
财政年份:2011
-
负责人:Muhammad Ashraf
-
依托单位:
Angiomyogenesis With Myoblast Derived iPS Cells
-
批准号:8280308
-
项目类别:
-
资助金额:$68.37万
-
财政年份:2011
-
负责人:Muhammad Ashraf
-
依托单位:
iPS cells-derived progenitor cells for angiomyogenesis
-
批准号:8521360
-
项目类别:
-
资助金额:$58.6万
-
财政年份:2011
-
负责人:Muhammad Ashraf
-
依托单位:
Angiomyogenesis With Myoblast Derived iPS Cells
-
批准号:8088680
-
项目类别:
-
资助金额:$68.37万
-
财政年份:2011
-
负责人:Muhammad Ashraf
-
依托单位:
iPS cells-derived progenitor cells for angiomyogenesis
-
批准号:8205715
-
项目类别:
-
资助金额:$56.38万
-
财政年份:2011
-
负责人:Muhammad Ashraf
-
依托单位:
Wnt11 signaling in stem cell survival and cardiac regeneration
-
批准号:8011255
-
项目类别:
-
资助金额:$38.11万
-
财政年份:2010
-
负责人:Muhammad Ashraf
-
依托单位:
Wnt11 signaling in stem cell survival and cardiac regeneration
-
批准号:8475403
-
项目类别:
-
资助金额:$36.99万
-
财政年份:2010
-
负责人:Muhammad Ashraf
-
依托单位:
Wnt11 signaling in stem cell survival and cardiac regeneration
-
批准号:8139120
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2010
-
负责人:Muhammad Ashraf
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: